Genome-wide association study identifies Alzheimer's risk variant in MS4A6A influencing cerebrospinal fluid sTREM2 levels

Neurobiol Aging. 2019 Dec:84:241.e13-241.e20. doi: 10.1016/j.neurobiolaging.2019.05.008. Epub 2019 May 21.

Abstract

The triggering receptor expressed on myeloid cells 2 (TREM2) gene has been reported to increase the risk of Alzheimer's disease (AD). The soluble TREM2 protein (sTREM2) in cerebrospinal fluid (CSF) was also associated with AD. However, the role of sTREM2 in AD and its genetic modifiers remain unclear. We carried out a genome-wide association study for CSF sTREM2 levels using participants from the Alzheimer's Disease Neuroimaging Initiative and validated the significant association in an independent cohort from Chinese Alzheimer's Biomarker and LifestylE study. rs7232 in membrane spanning 4-domains A6A (MS4A6A) gene was associated with CSF sTREM2 levels at genome-wide significance (p = 1.42 × 10-15). The locus influences CSF sTREM2 levels especially in nondemented individuals. And the association was replicable in the validation cohort from Chinese Alzheimer's Biomarker and LifestylE study (p = 0.0106). Besides, the expressions of MS4A6A and TREM2 were correlated in brain regions (p < 2 × 10-16). The findings of our study suggest that the AD risk variant in the MS4A6A gene participates in the regulation of sTREM2.

Keywords: Alzheimer's disease; Genome-wide association study; MS4A6A; TREM2.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Alzheimer Disease / genetics*
  • Genome-Wide Association Study*
  • Humans
  • Membrane Glycoproteins / cerebrospinal fluid*
  • Receptors, Immunologic
  • Risk

Substances

  • Membrane Glycoproteins
  • Receptors, Immunologic
  • TREM2 protein, human